Bank Of New York Mellon Corp Tricida, Inc. Transaction History

Bank Of New York Mellon Corp

$521 Trillion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $14,426 - $1.29 Million	103,049 New	103,049 $15,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $99,720 - $159,364	11,718 Added 13.09%	101,234 $1.06 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $552,906 - $896,298	75,637 Added 544.97%	89,516 $866,000
Q1 2022 May 11, 2022	SELL	$7.35 - $10.63 $2,917 - $4,220	-397 Reduced 2.78%	13,879 $114,000
Q2 2021 Aug 11, 2021	SELL	$3.95 - $5.41 $352,952 - $483,410	-89,355 Reduced 86.22%	14,276 $61,000

Q1 2021 May 13, 2021	SELL	$4.52 - $7.8 $30,668 - $52,923	-6,785 Reduced 6.14%	103,631 $548,000
Q4 2020 Feb 09, 2021	SELL	$4.37 - $9.46 $869 - $1,882	-199 Reduced 0.18%	110,416 $778,000
Q3 2020 Nov 12, 2020	SELL	$8.56 - $26.93 $42,346 - $133,222	-4,947 Reduced 4.28%	110,615 $1 Million
Q2 2020 Aug 12, 2020	BUY	$21.21 - $31.55 $520,832 - $774,741	24,556 Added 26.98%	115,562 $3.18 Million
Q1 2020 May 06, 2020	BUY	$18.43 - $38.04 $1,400 - $2,891	76 Added 0.08%	91,006 $2 Million
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $210,278 - $310,515	7,104 Added 8.47%	90,930 $3.43 Million
Q3 2019 Nov 07, 2019	SELL	$29.87 - $42.22 $565,827 - $799,773	-18,943 Reduced 18.43%	83,826 $2.59 Million
Q2 2019 Aug 12, 2019	BUY	$31.16 - $39.46 $652,334 - $826,095	20,935 Added 25.58%	102,769 $4.06 Million
Q1 2019 May 14, 2019	BUY	$19.96 - $38.62 $617,921 - $1.2 Million	30,958 Added 60.85%	81,834 $3.16 Million
Q4 2018 Feb 11, 2019	BUY	$23.57 - $32.33 $383,130 - $525,524	16,255 Added 46.95%	50,876 $1.2 Million
Q3 2018 Nov 09, 2018	BUY	$22.5 - $39.35 $778,972 - $1.36 Million	34,621 New	34,621 $0

Others Institutions Holding TCDA

# of Institutions

Shares Held

30K

Call Options Held

124K

Put Options Held

46.5K

View Full List

About Tricida, Inc.

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

More about TCDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account